Skip to main content
COVID-19 In Vitro Diagnostic Devices and Test Methods Database

Scientific literature on COVID-19 Test Methods and Devices - detail

Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation

Detection Principle
Testing Method Category
Other Immuno assay
Testing Method
ARCHITECT SARS-CoV-2 N IgG Immunoassay (Abbot, Illinois, U.S.A), LIAISON SARS-CoV-2 S1/S2 IgG (Diasorin, Saluggia,Italy), Elecsys N Anti-SARS-CoV-2 (Roche, Mannheim, Germany), VIDAS SARS-COV-2 RBD IgG (BioMérieux, Marcy-l'Etoile, France), Siemens SARS-CoV-2 RBD Total (COV2T) (Siemens, NY, USA), Access SARS-CoV-2 RBD IgG assay (Beckman-Coulter, CA, U.S.A.) and in house RBD ELISA test
Reported Performance
Specificity: 99.5% (Abbott), 98.7% (Diasorin), 98.9% (VIDAS IgG), 100% (Roche and Beckman), 97.7% (ELISA), 98.8% (siemens) ; Sensitivity: 84.7% (Abbott), 82.4% (Diasorin), 89.3% (VIDAS IgG), 89% (Roche), 89.4% (ELISA), 81.5% (Beckman), 85.9% (Siemens)
Sample Size
3089 samples

The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements